A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)
A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
Key Inclusion Criteria for Parts A and B
Documentation of PH1 as determined by genetic analysis confirming pathogenic mutations in the alanine-glyoxylate aminotransferase (AGXT) gene (valid historical laboratory data will be reviewed and approved by the Sponsor)
Age at time of signing the informed consent/assent form:
24-hour UOx ≥0.7 mmol/24 hours/1.73 m²
eGFR ≥30 mL/min/1.73m²
Weight ≤90 kg
Key Exclusion Criteria for Parts A and B
arbortrials@arbor.bio617-500-8941
Rochester, Minnesota 55905, United States
800-664-4542
04 27 85 61 28
info@knz-bonn.de0228 6883860
+216 74 244 511
ClinicalResearchFacilityEnquiries@uhb.nhs.uk0121 371 3170
rf.crf@nhs.net020 7794 0500 ext. 32038